Burning Rock Biotech (FRA:6BU0) Interest Expense: €-0.01 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6BU0 Burning Rock Biotech Ltd FRA:6BU0
63 GF Score
Price €7.45
GF Value €5.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Interest Expense?

Burning Rock Biotech FRA:6BU0 +0.68% 63 Interest Expense is €-0.01 Mil as of Mar. 2026. GuruFocus rates FRA:6BU0 with a GF Score™ of 63/100 and a GF Value™ of €5.57 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Burning Rock Biotech's interest expense for the three months ended in Mar. 2026 was € -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Burning Rock Biotech's Operating Income for the three months ended in Mar. 2026 was € -2.37 Mil. Burning Rock Biotech's Interest Expense for the three months ended in Mar. 2026 was € -0.00 Mil. Burning Rock Biotech did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Burning Rock Biotech  (FRA:6BU0) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Burning Rock Biotech's Interest Expense for the three months ended in Mar. 2026 was €-0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-2.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €3.71 Mil.

Burning Rock Biotech's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Burning Rock Biotech did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Burning Rock Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Burning Rock Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burning Rock Biotech Interest Expense Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only -0.21 0.00 0.00 0.00 -0.00

Burning Rock Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 -0.00
FRA:6BU0
63GF Score
Burning Rock Biotech Ltd FRA:6BU0
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Burning Rock Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.01 Mil mean?
Burning Rock Biotech (FRA:6BU0) has a Interest Expense of €-0.01 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Interest Expense too high?
Burning Rock Biotech's current Interest Expense is €-0.01 Mil. Overall, Burning Rock Biotech has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Interest Expense compare to XGN and IDXG?
Burning Rock Biotech's Interest Expense of €-0.01 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Diagnostics & Research company?
A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Interest Expense is €-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.57, compared to a current price of €7.45 — trading 33.8% above its estimated fair value. The current Interest Expense is €-0.01 Mil. Burning Rock Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Interest Expense is €-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of €7.45 is trading 33.8% above its estimated GF Value™ of €5.57. GuruFocus considers Burning Rock Biotech to be Modestly Undervalued.

Key valuation signals for FRA:6BU0:

  • Interest Expense: €-0.01 Mil
  • GF Value™: €5.57 vs. price of €7.45 (33.8% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges BNR:USA
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
63GF Score

Get the complete analysis for FRA:6BU0

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.45
Price
€5.57
GF Value